英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

Manichee    
n. 摩尼教徒

摩尼教徒

Manichee
adj 1: of or relating to Manichaeism [synonym: {Manichaean},
{Manichean}, {Manichee}]
n 1: an adherent of Manichaeism [synonym: {Manichaean}, {Manichean},
{Manichee}]


请选择你想看的字典辞典：
单词字典翻译
Manichee查看　Manichee　在百度字典中的解释百度英翻中〔查看〕
Manichee查看　Manichee　在Google字典中的解释Google英翻中〔查看〕
Manichee查看　Manichee　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Nexletol shows CLEAR benefit in cardiovascular outcome trial
    New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    U S FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
  • Bempedoic Acid and Cardiovascular Outcomes in Statin . . .
    The risk of death from cardiovascular causes, nonfatal stroke, or nonfatal myocardial infarction (the first key secondary end point) was 15% lower with bempedoic acid than with placebo, and the
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • SGLT-2 Inhibitors in Heart Failure: A Review of Current . . .
    Sodium-glucose co-transporter 2 (SGLT-2) inhibitors are the latest addition to guideline-directed medical therapy in heart failure (HF) with reduced ejection fraction with recent trials suggesting a significant reduction in adverse cardiovascular
  • What Is NEXLETOL®? - Learn More About This Nonstatin Option
    The most common side effects of NEXLETOL in people with heart problems include: Kidney problems, anemia, increased liver enzymes, muscle spasms, and gallstones NEXLETOL can cause serious side effects, including: Increased levels of uric acid in the blood, which can lead to gout, a painful joint condition
  • FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to . . .
    Esperion announced that the FDA approved broad new label expansions for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention patients
  • SGLT2 Inhibitors Shown to Improve Outcomes in Amyloid Heart . . .
    SGLT2 inhibitors were associated with significantly lower 12-month all-cause mortality and hospitalization in patients with heart failure due to ATTR, a study shows
  • NEXLIZET® NEXLETOL® Other Outcomes Trial Information
    The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of NEXLIZET and NEXLETOL, at an incidence of ≥2% and 0 5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    The U S approvals of NEXLIZET and NEXLETOL for cardiovascular risk reduction and LDL-C lowering were based on data generated from the CLEAR Outcomes trial, which was published in the New England Journal of Medicine in March 2023, assessing the effect of NEXLETOL on cardiovascular outcomes in nearly 14,000 patients with, or at high risk, of





中文字典-英文字典  2005-2009